Investigational drug · Phase 3
HMPL-523
Also called: Sovleplenib
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Warm Antibody Autoimmune Hemolytic Anemia, Primary Immune Thrombocytopenia (ITP).
Phase 3Last checked: Nov 19, 2026Latest source record: May 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
15
Any phase or sponsor naming "HMPL-523"
First trial start
2021
Oct 27, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HMPL-523", any sponsor or status.
- Phase 113
Conditions studied
As listed on its trial records.
- Warm Antibody Autoimmune Hemolytic Anemia
- Primary Immune Thrombocytopenia (ITP)
Approved drugs for the same conditions: Anemia · Immune thrombocytopenia · Hematology and blood cancers · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "HMPL-523" as an intervention, largest first.
- Phase III Study on HMPL-523 for Treatment of ITPPivotal-lookingCompleted
HutchmedIndustry
NCT05029635 · 272 participants · Start Oct 27, 2021 · Primary completion May 16, 2025
Drug: HMPL-523; Placebo · For: Primary Immune Thrombocytopenia (ITP)
Sites: Hefei, China; Beijing, China; Fuzhou, China · 37 sites in all
Hutchison Medipharma LimitedIndustry
NCT02857998 · 134 participants · Start Dec 27, 2016 · Primary completion Jun 30, 2021
Drug: HMPL-523 · For: Mature B-cell Neoplasms
Sites: Beijing, China; Shanghai, China
- A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523Pivotal-lookingCompleted
Hutchison Medipharma LimitedIndustry
NCT02105129 · 118 participants · Start May 2014 · Primary completion Dec 2015
Drug: HMPL-523; Placebo · For: Rheumatoid Arthritis (RA)
Sites: Melbourne, Australia
- HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaPivotal-lookingActive, not recruiting
HutchmedIndustry
NCT05535933 · 111 participants · Start Sep 30, 2022 · Primary completion Nov 25, 2025
Drug: HMPL-523(300mg PO QD); Placebo · For: Warm Antibody Autoimmune Hemolytic Anemia
Sites: Fuyang, China; Fuzhou, China; Lanzhou, China · 39 sites in all
Hutchison Medipharma LimitedIndustry
NCT02503033 · 78 participants (planned) · Start Nov 2015 · Primary completion Dec 2020
Drug: HMPL-523 · For: Hematologic Malignancies
Sites: Canberra, Australia; Albury, Australia; Liverpool, Australia · 12 sites in all
HutchmedIndustry
NCT03779113 · 69 participants · Start Sep 26, 2019 · Primary completion Feb 26, 2025
Drug: HMPL-523 · For: Non Hodgkin Lymphoma
Sites: Anaheim, California; Downey, California; Oxnard, California · 32 sites in all
HutchmedIndustry
NCT07331194 · 54 participants · Start Oct 28, 2025 · Primary completion Nov 28, 2025
Drug: HMPL-523 Acetate Tablets (Test Formulation); HMPL-523 Acetate Tablets (Reference Formulation) · For: Healthy
Sites: Jinan, China
Hutchison Medipharma LimitedIndustry
NCT03951623 · 45 participants · Start Aug 12, 2019 · Primary completion Oct 30, 2021
Drug: HMPL-523; Placebo · For: Immune Thrombocytopenia (ITP)
Sites: Tianjin, China
Hutchison Medipharma LimitedIndustry
NCT05318820 · 39 participants · Start Jun 1, 2022 · Primary completion Jul 31, 2022
Drug: HMPL-523 · For: Healthy Subject
Sites: Shanghai, China
HutchmedIndustry
NCT05720767 · 28 participants · Start Nov 4, 2022 · Primary completion Feb 5, 2023
Drug: HMPL-523; Itraconazole and 1 more · For: Relapsed or Refractory Lymphoma
Sites: Austin, Texas
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and mechanism of action of sovleplenib for aplastic anemia.
Sheng T, Sun W, Xin S, et al. · Hematology 2026
- Phase 1, open-label, multicenter study of sovleplenib (HMPL-523) in patients with relapsed or refractory lymphoma.
Strati P, Chraniuk D, González-Barca E, et al. · Blood Adv 2026
- Comparative Efficacy and Safety of Bruton Tyrosine Kinase and Spleen Tyrosine Kinase Inhibitors in Immune Thrombocytopenia: A Network Meta-Analysis of Clinical Trials.
Abulehia A, Alshareef RB, Khateeb S, et al. · EJHaem 2026
- Management of autoimmune hemolytic anemia.
Barcellini W, Fattizzo B · Hematology Am Soc Hematol Educ Program 2025
- Beneath the surface in autoimmune hemolytic anemia: pathogenetic networks, therapeutic advancements and open questions.
Costa A, Mulas O, Mereu AM, et al. · Front Immunol 2025
- Efficacy and Safety of Syk and BTK Inhibitors in Immune Thrombocytopenia: A Comprehensive Review of Emerging Evidence.
Heidari A, Mazid AS, Behroozfar M, et al. · Mediators Inflamm 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.